罗替戈汀透皮贴治疗帕金森病神经精神症状的Meta分析

摘要
图/表
参考文献(17)
相关文章 (15)

全文: PDF (0 KB) HTML (37 KB)
输出: BibTeX | EndNote (RIS)

摘要目的系统评价罗替戈汀透皮贴对帕金森病（PD）神经精神症状的治疗效果。方法检索Pubmed、Clinic trails、Cochrane Library、Embase数据库，检索时间从建库到2017年9月1日，搜集罗替戈汀透皮贴治疗PD神经精神症状的RCT文献。由2名研究者严格按照纳入与排除标准独立筛选文献、提取资料并评价质量，由第3位研究者审核，使用RevMan 5.3软件进行Meta分析。结果最终纳入8个随机对照试验，共计1675例PD患者。Meta分析结果显示，罗替戈汀透皮贴在NMSS的情绪/淡漠方面、BDI-Ⅱ、AS、NMSS的睡眠/疲劳方面、PDQ-8、PDQ-39的评分上优于对照组，差异有统计学意义[NMSS 的情绪/淡漠方面：MD=-2.5，95%CI（-4.11，-0.89），P=0.002；BDI-Ⅱ：MD=-1.19，95%CI（-2.30，-0.08），P=0.04；AS：MD=-1.56，95%CI（-2.67，-0.45），P=0.006；NMSS 的睡眠/疲劳方面：MD=-2.03，95%CI（-3.08，-0.98），P=0.001；PDQ-8：MD=-4.93，95%CI（-6.79，-3.07），P＜0.00001；PDQ-39：MD=-3.52，95%CI（-5.25，-1.79），P＜0.0001]。 PDSS-2 的研究间偏倚过大。 SHAPS 的结果差异无统计学意义[MD=-0.12，95%CI（-0.58，0.34），P=0.61]。结论罗替戈汀透皮贴与对照组相比可有效改善PD神经精神症状，提高患者生活质量，结论尚需进一步研究。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	王昊天
	何屹
	余刚

关键词 ：帕金森病, 罗替戈汀透皮贴, 神经精神症状, Meta分析

Abstract：ObjectiveTo systematically evaluate the therapeutic effect of rotigotine transdermal patch in the treatment of neuropsychiatric symptoms of Parkinson′s disease(PD).Methods PubMed,Clinic trails,Cochrane Library,Embase database were searched.The search time was from database building to September 1,2017.RCT literature of rotigotine transdermal patch in the treatment of PD neuropsychiatric symptoms was collected.The inclusion and exclusion criteria were strictly followed by two investigators for independent screening of documents,extracting information and evaluating the quality,and the literature was reviewed by the third investigator.Meta-analysis was performed using RevMan 5.3 software.Results Finally,8 randomized controlled trials were included,with a total of 1675 PD patients.Meta analysis showed that,in the aspects of mood/indifference of NMSS,sleep/fatigue of BDI-Ⅱ,AS and NMSS,the scores of PDQ-8 and PDQ-39,rotigotine transdermal patch was superior to the control group,and the difference was statistically significant[emotional/indifferenceofNMSS：MD=-2.5,95%CI（-4.11,-0.89）,P=0.002;BDI-Ⅱ：MD=-1.19,95%CI（-2.30,-0.08）,P=0.04;AS：MD=-1.56,95%CI （-2.67,-0.45）,P=0.006;sleep/fatigue of NMSS：MD=-2.03,95%CI （-3.08,-0.98）,P=0.001;PDQ-8：MD=-4.93,95%CI（-6.79,-3.07）,P＜0.00001;PDQ-39：MD=-3.52,95%CI （-5.25,-1.79）,P＜0.0001].The study bias of PDSS-2 was too large.The results of SHAPS were not statistically significant[MD=-0.12,95%CI （-0.58,0.34）,P=0.61].ConclusionRotigotine Transdermal Patch can effectively improve PD neuropsychiatric symptoms and improve the quality of life of patients compared with the control group.The conclusion needs to be further studied.

Key words： Parkinson disease Rotigotine Transdermal Patch Neuropsychiatric symptoms Meta analysis

通讯作者: 余刚（1971-），男，硕士研究生，主任医师，研究方向：帕金森病

作者简介: 王昊天（1991-），男，2015级在读硕士研究生，研究方向：帕金森病

引用本文:

王昊天；何屹；余刚. 罗替戈汀透皮贴治疗帕金森病神经精神症状的Meta分析[J]. 中国当代医药, 2018, 25(7): 8-12.
WANG Hao-tian ；HE Yi；YU Gang. Meta analysis of Rotigotine Transdermal Patches in the treatment of neuropsychiatric symptoms in the patients with Parkinson′s disease. 中国当代医药, 2018, 25(7): 8-12.

链接本文:

http://dangdaiyiyao.com/CN/ 或 http://dangdaiyiyao.com/CN/Y2018/V25/I7/8

[1]	Schrag A.Psychiatric aspects of Parkinson′s disease-an update[J].J Neurol，2004，251（7）：795-804.
[2]	Aarsland D，Larsen JP，Lim NG，et al.Range of neuropsychiatric disturbances in patients with Parkinson′s disease[J].J Neurol Neurosurg Psychiatry，1999，67（4）：492-496.
[5]	Moraga-Amaro R，Gonzalez H，Pacheco R，et al.Dopamine receptor D3 deficiency results in chronic depression and anxiety[J].Behav Brain Res，2014，274：186-193.
[9]	Barone P.Neurotransmission in Parkinson′s disease：beyond dopamine[J].Eur J Neurol，2010，17（3）：364-376.
[3]	Chaudhuri KR，Healy DG，Schapira AH.Non-motor symptoms of Parkinson′s disease：diagnosis and management[J].Lancet Neurol，2006，5（3）：235-245.
[4]	Leentjens AFG，Koester J，Fruh B，et al.The effect of pramipexole on mood and motivational symptoms in Parkinson′s disease：a Meta-analysis of placebo-controlled studies[J].Clin Ther，2009，31（1）：89-98.
[6]	Liu J，Dong J，Wang L，et al.Comparative efficacy and acceptability of antidepressants in Parkinson′s disease：a network Meta-analysis[J].PLoS One，2013，8（10）：e76651.
[7]	Elshoff JP，Cawello W，Andreas JO，et al.An update on pharmacological，pharmacokinetic properties and drug-drug interactions of rotigotine transdermal system in Parkinson′s disease and restless legs syndrome[J].Drugs，2015，75（5）：487-501.
[8]	Elshoff JP，Braun M，Andreas JO，et al.Steady-state plasma concentration profile of transdermal rotigotine：an integrated analysis of three，open-label，randomized，phase Ⅰ multiple dose studies[J].Clin Ther，2012，34（4）：966-978.
[10]	Antonini A，Bauer L，Dohin E，et al.Effects of rotigotine transdermal patch in patients with Parkinson′s disease presenting with non-motor symptoms-results of a double-blind，randomized，placebo-controlled trial[J].Eur J Neurol，2015，22（10）：1400-1407.
[11]	Bhidayasiri R，Sringean J，Chaiwong S，et al.Rotigotine for nocturnal hypokinesia in Parkinson′s disease：quantitative analysisofefficacyfromarandomized，placebo-controlledtrial using an axial inertial sensor[J].Parkinsonism Relat Disord，2017，44：124-128.
[12]	Chung SJ，Asgharnejad M，Bauer L，et al.Evaluation of rotigotine transdermal patch for the treatment of depressive symptoms in patients with Parkinson′s disease[J].Expert Opin Pharmacother，2016，17（11）：1453-1461.
[13]	Hauser RA，Slawek J，Barone P，et al.Evaluation of rotigotine transdermal patch for the treatment of apathy and motor symptoms in Parkinson′s disease[J].BMC Neurol，2016，16（1）：90.
[14]	Mizuno Y，Nomoto M，Hasegawa K，et al.Rotigotine vs ropinirole in advanced stage Parkinson′s disease：a double-blind study[J].Park Relat Disord，2014，20（12）：1388-1393.
[15]	Poewe WH，Rascol O，Quinn N，et al.Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson′s disease：adouble-blind，double-dummy，randomised controlled trial[J].Lancet Neurol，2007，6（6）：513-520.
[16]	Rascol O，Zesiewicz T，Chaudhuri KR，et al.A randomized controlled exploratory pilot study to evaluate the effect of rotigotine transdermal patch on parkinson′s disease-associated chronic pain[J].J Clin Pharmacol，2016，56（7）：852-861.
[17]	Trenkwalder C，Kies B，Rudzinska M，et al.Rotigotine effects on early morning motor function and sleep in Parkinson′s disease：A double-blind，randomized，placebo-controlled study （RECOVER）[J].Mov Disord，2011，26（1）：90-99.